Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREV-HAP
2020-000620-18Phase 2Terminated
- Sponsor
- CHU de Nantes
- Start
- Feb 2021
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hospital-acquired pneumonia (HAP) comparing interferon gamma-1b with placebo (2 arms). Primary endpoint: Composite of all-cause mortality and/or hospital-acquired pneumonia by day 28. Started Feb 2021; status: terminated.
02
Drugs
interferon gamma-1b
03
Conditions
hospital-acquired pneumonia (HAP)
Beyond the preview
Go deeper on 2020-000620-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000620-18.